<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27450" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Portal Hypertension</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oliver</surname>
            <given-names>Tony I.</given-names>
          </name>
          <aff>University Of South Dakota</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Bashar</given-names>
          </name>
          <aff>SUNY Upstate University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>John</surname>
            <given-names>Savio</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tony Oliver declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bashar Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Savio John declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27450.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Portal hypertension is increased pressure within the portal venous system. It is determined by increased portal pressure gradient (the difference in pressures between the portal venous pressure and the pressure within the inferior vena cava or the hepatic vein. This pressure gradient is normally less than or equal to 5 mmHg. A pressure gradient of 6 mmHg or more between the portal and hepatic veins (or inferior vena cava) suggests the presence of portal hypertension in most cases. Portal hypertension is the most frequent cause of hospitalization, variceal bleed, liver transplantation, and death in patients with cirrhosis. This activity illustrates the evaluation and management of portal hypertension and highlights the role of the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the most common causes of portal hypertension.</p></list-item><list-item><p>Review the complication caused by portal hypertension.</p></list-item><list-item><p>Summarize the treatment and management options available for portal hypertension.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team to ensure patients affected by portal hypertension receive appropriate management and education thereby improving their outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27450&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27450">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27450.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Portal hypertension is increased pressure within the portal venous system. It is determined&#x000a0;by the increased portal pressure gradient (the difference in pressures between the portal venous pressure and the pressure within the inferior vena cava or the hepatic vein. This pressure gradient is normally less than or equal to 5 mmHg. A pressure gradient of 6 mmHg or more between the&#x000a0;portal and hepatic veins (or inferior vena cava) suggests the presence of portal hypertension in most cases.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref> When the pressure gradient is greater than 10 mmHg, portal hypertension becomes clinically significant. A pressure gradient between 5&#x000a0;to 9 mmHg usually reflects subclinical disease. This&#x000a0;gradient&#x000a0;is measured by the determination of the hepatic venous pressure gradient (HVPG).<xref ref-type="bibr" rid="article-27450.r1">[1]</xref> Portal hypertension develops when resistance to portal blood flow&#x000a0;increases. This&#x000a0;resistance often occurs within the liver, as in cirrhosis. It can also be outside of the liver, such as prehepatic in portal vein thrombosis or posthepatic in the case of constrictive pericarditis or Budd-Chiari syndrome. Identification of the level of resistance to portal blood flow allows the determination of the cause of portal hypertension.&#x000a0;This condition&#x000a0;is the most frequent cause of hospitalization, variceal bleed, liver transplantation, and death in patients with cirrhosis. Gilbert and Carnot coined the term "portal hypertension" in 1902.</p>
      </sec>
      <sec id="article-27450.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Numerous causes of portal&#x000a0;hypertension exist. The etiology can classify as prehepatic, intrahepatic, or posthepatic reasons.&#x000a0;</p>
        <p>The common causes of pre-hepatic etiology are either due to increased blood flow or obstruction&#x000a0;within the portal vein or splenic vein.&#x000a0;Instances of increased blood flow include&#x000a0;idiopathic tropical splenomegaly, arterio-venous malformations, or fistula. A blockage&#x000a0;within the portal or splenic vein may be due to thrombosis or to invasion or compression of these veins by the tumor.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref>&#x000a0;</p>
        <p>Intrahepatic causes subclassify into pre-sinusoidal, sinusoidal, or post-sinusoidal. Pre-sinusoidal intrahepatic causes can be produced by schistosomiasis, congenital hepatic fibrosis, early primary biliary cholangitis, sarcoidosis, chronic active hepatitis, and toxins such as vinyl chloride, arsenic, and copper. Sinusoidal causes arise from cirrhosis, alcoholic hepatitis, vitamin A intoxication, or cytotoxic drugs. Post-sinusoidal causes result from sinusoidal obstruction syndrome or veno-occlusive disease.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref></p>
        <p>Finally, posthepatic causes can be at the level of the heart, hepatic vein, as in Budd-Chiari syndrome, or inferior vena cava. Posthepatic causes&#x000a0;at the level of the heart are due to a rise in atrial pressure, as in constrictive pericarditis. If these causes occur at the level of the inferior vena cava, it is due to stenosis, thrombosis, webs, or tumor invasion.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref></p>
      </sec>
      <sec id="article-27450.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Cirrhosis&#x000a0;of the liver is the most prevalent cause of portal hypertension in the Western world.&#x000a0;However, schistosomiasis is the most frequent cause in the African continent where schistosomiasis is endemic.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref></p>
      </sec>
      <sec id="article-27450.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The superior mesenteric vein and splenic vein join to form the portal vein. It drains into the liver before dividing into the right and left portal veins into both lobes, respectively. It supplies two-thirds of the blood to the liver. The portal vein pressure is typically between 1 to 4 millimeters of mercury more than the hepatic vein pressure. This&#x000a0;pressure differential enables blood to flow through the liver into the systemic circulation. The veins do not have valves. If there is resistance to the flow of blood in the portal venous tract, it leads to elevated portal venous pressure, as seen in portal hypertension. The resistance occurs more commonly within the liver, as seen in cirrhosis, but it can also be pre-hepatic or post-hepatic.</p>
        <p>The increased resistance within the organ can be due to structural or dynamic changes. Structural changes are due to the alteration of hepatic microcirculation. Such alteration results from hepatic stellate cell activation and the resultant fibrosis, regenerative nodules, vascular occlusion, and angiogenesis. The increased production of endothelial vasoconstrictors and decreased release of vasodilators within the liver leads to sinusoidal constriction.<xref ref-type="bibr" rid="article-27450.r2">[2]</xref> Portal hypertension stemming from this is augmented and perpetuated by the increased blood flow within the splanchnic circulation. This increased blood flow is due to the increased release of splanchnic vasodilators because of increased shear stress and reduced effective arterial volume. Thus portal hypertension is a result of both increased resistance to portal venous flow and increased portal blood flow due to splanchnic vasodilation. When the portal pressure remains elevated, developing collaterals attempt to reduce it.<xref ref-type="bibr" rid="article-27450.r2">[2]</xref></p>
      </sec>
      <sec id="article-27450.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients usually have no symptoms until complications arise. Hematemesis from bleeding varices is the most common presentation. Melena without hematemesis&#x000a0;can also be present. As cirrhosis is the most common cause of portal hypertension, patients may present with stigmata of cirrhosis. These include jaundice, gynecomastia, palmar erythema, spider nevi, testicular atrophy, ascites, pedal edema, or asterixis due to hepatic encephalopathy.<xref ref-type="bibr" rid="article-27450.r3">[3]</xref> Prominent abdominal wall veins may be visible, which is an attempt to divert the portal blood flow via the paraumbilical veins into the caval system. In caput-medusae, the blood flow is away from the umbilicus. However, in inferior vena cava obstruction, the blood flow is toward the umbilicus to reach the superior vena cava system. A venous hum may be audible near the xiphoid process or umbilicus.<xref ref-type="bibr" rid="article-27450.r4">[4]</xref> Cruveilhier-Baumgarten syndrome is characterized by dilated abdominal wall veins and a low venous murmur at the umbilicus. An arterial systolic murmur is often due to hepatocellular carcinoma or alcoholic hepatitis.<xref ref-type="bibr" rid="article-27450.r4">[4]</xref> Splenomegaly is a reliable sign in the diagnosis of portal hypertension.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref> If the spleen is not enlarged on physical examination or imaging studies, the diagnosis of portal hypertension should be questioned. The pancytopenia seen with hypersplenism is due to reticuloendothelial hyperplasia. Therefore, it is not reversible by the reduction of portal hypertension via a portocaval shunt. While a firm liver supports a diagnosis of cirrhosis, hepatomegaly does not correlate with the severity of portal hypertension.</p>
      </sec>
      <sec id="article-27450.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The evaluation requires obtaining a good history and utilizing the relevant lab data. A complete blood count helps to distinguish the presence of thrombocytopenia, which is secondary to hypersplenism and anemia from gastrointestinal blood loss. A complete metabolic panel&#x000a0;identifies renal failure and liver enzyme elevation present in liver disease, viral hepatitis, and also hypoalbuminemia. A coagulation profile helps to identify the synthetic function of the liver. A prolonged prothrombin time, together with a low serum albumin level, reliably predicts hepatic synthetic function. Dopplers of portal vein can detect the presence of stenosis or thrombosis. Doppler of the portal vein will show either hepatopetal portal vein flow (toward liver) or hepatofugal portal vein flow (away from liver). These vary depending upon the degree of portal hypertension. Hepatopetal flow is normal.&#x000a0;An abdominal ultrasound can find evidence of cirrhosis of the liver, ascites, and splenomegaly.<xref ref-type="bibr" rid="article-27450.r5">[5]</xref> An endoscopy helps to look for the presence of varices. Finally, patients who present with ascites need paracentesis to determine their etiology, and to rule out spontaneous bacterial peritonitis.<xref ref-type="bibr" rid="article-27450.r6">[6]</xref><xref ref-type="bibr" rid="article-27450.r7">[7]</xref></p>
        <p>Measurement of portal pressure is often not required to make a diagnosis of portal hypertension in cases where clinical signs and symptoms are readily manifest. The patency of the portal and hepatic veins may be assessed by duplex Doppler ultrasound, magnetic resonance, or computed tomography angiography. Direct measurement of portal pressure is invasive, expensive, and complicated. The indirect method of portal pressure determination is thus the preferred method. The direct method of measurement is by cannulation of the hepatic vein&#x000a0;and measuring free hepatic vein pressure. The indirect method is done by balloon occlusion of the hepatic vein and&#x000a0;measurement of the wedged hepatic vein pressure.&#x000a0;These measurements are used to calculate the hepatic venous pressure gradient.<xref ref-type="bibr" rid="article-27450.r1">[1]</xref></p>
      </sec>
      <sec id="article-27450.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of portal hypertension depends on its cause. If there are reversible causes, the clinician should attempt to correct them. For example, if there is thrombosis in the portal vein or the inferior vena cava due to a hypercoagulable state, it needs anticoagulation.&#x000a0;</p>
        <p>Other treatment options are based on concurrent complications. Patients who have cirrhosis of the liver should undergo endoscopy to screen for varices. If large varices or varices with high-risk stigmata are present, the patient should start therapy with non-selective beta-blockers and/or endoscopic variceal ligation.<xref ref-type="bibr" rid="article-27450.r8">[8]</xref> Patients with an acute variceal bleed should receive endoscopic therapy&#x000a0;or the placement of a transjugular intrahepatic portosystemic shunt. They should also start taking empiric antibiotics for prophylaxis against spontaneous bacterial peritonitis.<xref ref-type="bibr" rid="article-27450.r9">[9]</xref> Ascites treatments depend on&#x000a0;the severity of the underlying liver disease and the patient's response to therapy. These treatments include&#x000a0;dietary sodium restriction, diuretics such as spironolactone in combination with furosemide, large-volume paracentesis, transjugular intrahepatic portosystemic shunt placement, and liver transplantation.<xref ref-type="bibr" rid="article-27450.r10">[10]</xref> The definitive treatment for portal hypertension caused by cirrhosis is liver transplantation.</p>
      </sec>
      <sec id="article-27450.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Budd-Chiari syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Constrictive pericarditis&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myeloproliferative disease&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Polycystic kidney disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tricuspid regurgitation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Vitamin A deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wilson disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27450.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis depends on the underlying etiology of portal hypertension.</p>
      </sec>
      <sec id="article-27450.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of portal hypertension include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Thrombocytopenia due to congestive hepatopathy</p>
          </list-item>
          <list-item>
            <p>Abdominal wall collaterals</p>
          </list-item>
          <list-item>
            <p>Variceal bleeding secondary to hemorrhage from gastroesophageal, anorectal, retroperitoneal, stomal, and other varices</p>
          </list-item>
          <list-item>
            <p>Acute bleeding or iron deficiency anemia due to chronic blood loss from portal hypertensive gastropathy, enteropathy,&#x000a0;or coagulopathy</p>
          </list-item>
          <list-item>
            <p>Ascites</p>
          </list-item>
          <list-item>
            <p>Spontaneous bacterial peritonitis</p>
          </list-item>
          <list-item>
            <p>Hepatic hydrothorax</p>
          </list-item>
          <list-item>
            <p>Hepatorenal syndrome</p>
          </list-item>
          <list-item>
            <p>Hepatic encephalopathy</p>
          </list-item>
          <list-item>
            <p>Hepatopulmonary syndrome</p>
          </list-item>
          <list-item>
            <p>Portopulmonary hypertension</p>
          </list-item>
          <list-item>
            <p>Cirrhotic cardiomyopathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27450.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Recommended consultations include gastroenterology, hepatology, and nephrology.</p>
      </sec>
      <sec id="article-27450.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should receive education about the ill effects of alcohol, a common cause of cirrhosis. The potential complications from portal hypertension should also&#x000a0;be explained. Knowledge will help patients to seek medical attention sooner, and decrease morbidity and mortality.</p>
      </sec>
      <sec id="article-27450.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>The common cause of portal hypertension is cirrhosis in Western countries. Noncirrhotic portal hypertension due to hepatic schistosomiasis and portal vein thrombosis is, however, the common cause in other parts of the world. Portal hypertension can remain asymptomatic until complications develop. Estimation of the hepatic venous pressure gradient and abdominal imaging studies can help determine the presence and etiology of portal hypertension in most cases.</p>
      </sec>
      <sec id="article-27450.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing patients with portal hypertension is challenging due to the complexity of the disease and multiple organ involvement. For this reason, the management is multidisciplinary with an interprofessional team of healthcare professionals required including a nurse, nurse practitioner, pharmacist, primary care physician, gastroenterologist, a hepatologist, and a transplant team with the possible need of a cardiologist and a pulmonologist, depending on the severity of the disease.&#x000a0;All healthcare workers should follow these patients and monitor them. Pharmacists should ensure that they are on the correct medications and are taking them correctly and are medication compliant, reporting any issues to the clinicians. Nurses will take care of these patients during their visits to the clinic or at the hospital if they get admitted. They will check their vitals, diet, and are the first to notice any changes in their mental status or hemodynamics. Clinicians should follow up with these patients on regular basis and make sure they are up to date on their immunizations, appropriate screening such as for&#x000a0;esophageal varices and hepatocellular carcinoma, diet, medications, functional status, and mental health.&#x000a0;Without proper management from an interprofessional team, the morbidity and mortality from portal hypertension are high. [Level 5]</p>
      </sec>
      <sec id="article-27450.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27450&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27450">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/portal-hypertension/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27450">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27450/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27450">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27450.s17">
        <title>References</title>
        <ref id="article-27450.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berzigotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seijo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reverter</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Assessing portal hypertension in liver diseases.</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-55</page-range>
            <pub-id pub-id-type="pmid">23363263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Pag&#x000e1;n</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gracia-Sancho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Functional aspects on the pathophysiology of portal hypertension in cirrhosis.</article-title>
            <source>J Hepatol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>458</fpage>
            <page-range>458-61</page-range>
            <pub-id pub-id-type="pmid">22504334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuppan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Afdhal</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Liver cirrhosis.</article-title>
            <source>Lancet</source>
            <year>2008</year>
            <month>Mar</month>
            <day>08</day>
            <volume>371</volume>
            <issue>9615</issue>
            <fpage>838</fpage>
            <page-range>838-51</page-range>
            <pub-id pub-id-type="pmid">18328931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Hardison</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <chapter-title>Auscultation of the Liver</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Walker</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hurst</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <source>Clinical Methods: The History, Physical, and Laboratory Examinations</source>
            <edition>3rd</edition>
            <publisher-name>Butterworths</publisher-name>
            <publisher-loc>Boston</publisher-loc>
            <year>1990</year>
            <pub-id pub-id-type="pmid">21250262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tchelepi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ralls</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Radin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Sonography of diffuse liver disease.</article-title>
            <source>J Ultrasound Med</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>9</issue>
            <fpage>1023</fpage>
            <page-range>1023-32; quiz 1033-4</page-range>
            <pub-id pub-id-type="pmid">12216750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Schiano</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Evaluation and Management of Cirrhotic Patients Undergoing Elective Surgery.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2019</year>
            <month>Jun</month>
            <day>15</day>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">31203525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alukal</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Thuluvath</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal Failure in Critically Ill Patients With Cirrhosis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>114</volume>
            <issue>8</issue>
            <fpage>1231</fpage>
            <page-range>1231-1237</page-range>
            <pub-id pub-id-type="pmid">31185004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Tsao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abraldes</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Berzigotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.</article-title>
            <source>Hepatology</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>310</fpage>
            <page-range>310-335</page-range>
            <pub-id pub-id-type="pmid">27786365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chavez-Tapia</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Barrientos-Gutierrez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tellez-Avila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mendez-Sanchez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gluud</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Uribe</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated Cochrane review.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>509</fpage>
            <page-range>509-18</page-range>
            <pub-id pub-id-type="pmid">21707680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27450.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedersen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Bendtsen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of cirrhotic ascites.</article-title>
            <source>Ther Adv Chronic Dis</source>
            <year>2015</year>
            <month>May</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>124</fpage>
            <page-range>124-37</page-range>
            <pub-id pub-id-type="pmid">25954497</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
